| Identification | Back Directory | [Name]
2-ATRACTYLENOLIDE | [CAS]
73069-14-4 | [Synonyms]
ASTEROLIDE
2-ATRACTYLENOLIDE
Atractylenolide Ⅱ
Atracylenolide II
Atractylenolide II, BR
Atractylenolide II (Asterolide)
(4aS,8aR,9aS)-4a,5,6,7,8,8a,9,9a-Octahydro-3,8a-dimethyl-5-methylenenaphtho[2,3-b]furan-2(4H)-one
Naphtho[2,3-b]furan-2(4H)-one, 4a,5,6,7,8,8a,9,9a-octahydro-3,8a-dimethyl-5-methylene-, (4aS,8aR,9aS)- | [Molecular Formula]
C15H20O2 | [MDL Number]
MFCD09037396 | [MOL File]
73069-14-4.mol | [Molecular Weight]
232.32 |
| Chemical Properties | Back Directory | [Melting point ]
150-152 °C(Solv: ethyl ether (60-29-7)) | [Boiling point ]
378.0±41.0 °C(Predicted) | [density ]
1.09±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
Soluble in chloroform | [form ]
powder | [color ]
White | [Major Application]
food and beverages | [InChI]
1S/C15H20O2/c1-9-5-4-6-15(3)8-13-11(7-12(9)15)10(2)14(16)17-13/h12-13H,1,4-8H2,2-3H3/t12-,13-,15+/m0/s1 | [InChIKey]
OQYBLUDOOFOBPO-KCQAQPDRSA-N | [SMILES]
O1[C@H]2C[C@@]3([C@@H](CC2=C(C1=O)C)C(=C)CCC3)C |
| Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO. It is derived from Atractylodes macrocephala Koidz. | [Uses]
food and beverages | [Definition]
ChEBI: Atractylenolide II is a sesquiterpene lactone. | [in vivo]
Atractylenolide II (12.5-25 mg/kg; Oral gavage; 14 days) has antitumor effect in a B16 xenograft mouse model[3].
Atractylenolide II (10-60 mg/kg/d; Intraperitoneal injection; 8 weeks) improves myocardial fibrosis and oxidative stress in spontaneously hypertensive rats[4]. | Animal Model: | C57/BL6 mice with a B16 xenograft model[3] | | Dosage: | 12.5 and 25 mg/kg | | Administration: | Oral gavage (i.g.); 14 days | | Result: | Significantly inhibited tumor growth.
Inhibited the activation/phosphorylation of STAT3 and Src.
|
| Animal Model: | Spontaneous hypertension rats[4] | | Dosage: | 10, 30 and 60 mg/kg/d | | Administration: | Intraperitoneal injection (i.p.); 8 weeks | | Result: | Improved the body weight of spontaneous hypertension rats and enhanced myocardial function in a dose-dependent manner.
Effectively reduced cardiomyocyte apoptosis.
Inhibited the Collagen I, α-SMA, Fibronectin and Vimentin mRNA and protein expression levels.
Ameliorated oxidative stress by improving the activities of SOD and GSH-PX and lowering the contents of H2O2 and MDA, which reached about 80%. |
| [IC 50]
p-STAT3 |
|
|